TransMedics Group (NASDAQ:TMDX) Price Target Raised to $85.00

TransMedics Group (NASDAQ:TMDX) had its target price boosted by JPMorgan Chase & Co. from $73.00 to $85.00 in a research note published on Friday morning,Benzinga reports. They currently have a neutral rating on the stock.

A number of other equities research analysts have also weighed in on the company. Zacks Research upgraded TransMedics Group from a “strong sell” rating to a “hold” rating in a research report on Monday, November 2nd. Wall Street Zen raised TransMedics Group from a “sell” rating to a “hold” rating in a research note on Saturday. UBS Group cut their price target on shares of TransMedics Group from $80.00 to $77.00 and set a “neutral” rating on the stock in a report on Wednesday, August 5th. Piper Sandler reiterated an “overweight” rating and issued a $100.00 price target (down from $120.00) on shares of TransMedics Group in a report on Wednesday, August 5th. Finally, Weiss Ratings raised shares of TransMedics Group from a “hold (c-)” rating to a “hold (c)” rating in a research report on Monday, August 31st. Five investment analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company’s stock. According to data from MarketBeat, TransMedics Group currently has an average rating of “Hold” and an average price target of $112.20.

TransMedics Group Stock Performance

TransMedics Group stock opened at $88.24 on Friday. The company has a current ratio of 4.53, a quick ratio of 4.15 and a debt-to-equity ratio of 1.46. The firm has a market cap of $3.05 billion, a P/E ratio of 23.91, a P/E/G ratio of 1.18 and a beta of 2.14. TransMedics Group has a 1-year low of $60.10 and a 1-year high of $156.00. The firm has a 50-day moving average of $79.61 and a 200-day moving average of $93.17.

TransMedics Group (NASDAQ:TMDX) last announced its quarterly earnings results on Thursday, November 5th. The company reported $0.51 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.30 by $0.21. The company had revenue of $203.01 million for the quarter, compared to the consensus estimate of $178.06 million. TransMedics Group had a return on equity of 13.30% and a net margin of 19.85%. TransMedics Group’s revenue was up 41.1% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.66 EPS. Sell-side analysts expect that TransMedics Group will post 1.50 EPS for the current year.

Insider Transactions at TransMedics Group

In other TransMedics Group news, Director David Weill purchased 1,336 shares of the stock in a transaction that occurred on Friday, September 11th. The stock was bought at an average cost of $81.63 per share, with a total value of $109,057.68. Following the transaction, the director directly owned 16,392 shares in the company, valued at approximately $1,338,078.96. The trade was a 8.87% increase in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 6.90% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On TransMedics Group

A number of hedge funds and other institutional investors have recently bought and sold shares of TMDX. Braidwell LP lifted its position in TransMedics Group by 85.1% in the 2nd quarter. Braidwell LP now owns 609,715 shares of the company’s stock valued at $40,497,000 after acquiring an additional 280,324 shares in the last quarter. Deutsche Bank AG purchased a new stake in TransMedics Group during the 2nd quarter valued at $14,415,000. Bank of New York Mellon Corp bought a new stake in shares of TransMedics Group in the 2nd quarter worth $12,869,000. Trek Financial LLC bought a new stake in shares of TransMedics Group in the 3rd quarter worth $11,989,000. Finally, Legal & General Group Plc purchased a new position in shares of TransMedics Group in the second quarter worth $5,286,000. Hedge funds and other institutional investors own 99.67% of the company’s stock.

TransMedics Group Company Profile

TransMedics Group, Inc is a medical technology company focused on improving organ transplantation. Its Organ Care System (OCS) is a portable platform that perfuses donor organs with warm, oxygenated blood and nutrients while they are outside the body. The company offers OCS systems for donor hearts, lungs and livers, along with related consumables and services.

The company also operates the National OCS Program in the United States, an integrated offering that combines its technology with organ procurement and transportation services.